IL-2Rα Antibody (H-6): sc-374034

IL-2Rα Antibody (H-6) is a mouse monoclonal IgG2a light chain antibody that detects IL-2Rα in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IL-2Rα, also known as CD25, plays a crucial role in immune response by serving as a high-affinity receptor for interleukin-2 (IL-2), a key cytokine involved in T cell proliferation and differentiation. IL-2Rα expression on T cells is essential for activation and survival, making IL-2Rα a critical component in immune response regulation. IL-2Rα is primarily located on activated T cell surfaces, where IL-2Rα facilitates IL-2 binding, leading to formation of the high-affinity IL-2 receptor complex when paired with β and γ chains. This complex initiates signaling pathways that promote T cell growth and function, underscoring IL-2Rα′s importance in both adaptive and innate immunity. Aberrations in IL-2Rα expression can be associated with various immune disorders and malignancies, highlighting IL-2Rα′s potential as a therapeutic target and biomarker in clinical settings. Anti-IL-2Rα antibody (H-6) serves as an invaluable tool for researchers studying T cell biology and immune regulation mechanisms.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IL-2Rα Antibody (H-6) References:

1. Treatment with the chimeric anti-IL-2Ralpha basiliximab affects both the IL-2 and IL-15 signalling pathways after clinical kidney transplantation.  |  Boelaars-van Haperen, MJ., et al. 2001. Transplant Proc. 33: 1007-8. PMID: 11267166
2. Effects of extracorporeal photoimmunotherapy on soluble IL-2Ralpha, TNF-RI, and CD8 in patients with steroid-resistant acute graft-versus-host disease.  |  Kokalj, A., et al. 2002. Clin Immunol. 104: 248-55. PMID: 12217335
3. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.  |  Bielekova, B., et al. 2006. Proc Natl Acad Sci U S A. 103: 5941-6. PMID: 16585503
4. A regulatory T cell-dependent novel function of CD25 (IL-2Ralpha) controlling memory CD8(+) T cell homeostasis.  |  Sharma, R., et al. 2007. J Immunol. 178: 1251-5. PMID: 17237369
5. Select plant tannins induce IL-2Ralpha up-regulation and augment cell division in gammadelta T cells.  |  Holderness, J., et al. 2007. J Immunol. 179: 6468-78. PMID: 17982035
6. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms.  |  Goette, NP., et al. 2010. Cytokine. 51: 67-72. PMID: 20483636
7. Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study.  |  Pardanani, A., et al. 2013. Leukemia. 27: 1430-3. PMID: 23318958
8. An in vitro study on suppressive effects of Leishmania major on IL-2Rα expression on peripheral human T lymphocyte.  |  Khodadadi, A., et al. 2013. Trop Biomed. 30: 526-34. PMID: 24189682
9. Biomarkers of systemic inflammation, soluble IL-2Rα and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients.  |  Buhelt, S., et al. 2021. Mult Scler Relat Disord. 54: 103140. PMID: 34304016
10. IL-15 induces the release of soluble IL-2Ralpha from human peripheral blood mononuclear cells.  |  Treiber-Held, S., et al. 1996. Clin Immunol Immunopathol. 79: 71-8. PMID: 8612353

The preferred IL-2Rα antibody is IL-2Rα Antibody (C-9): sc-393326.